Alkermes plc Reports Financial Results for Quarter Ended Sept. 30, 2013

Alkermes plc Reports Financial Results for Quarter Ended Sept. 30, 2013

— Quarterly Revenues of  Driven by 38% Year-Over-Year Growth From Portfolio of Five Key Commercial Products —

— Non-GAAP Diluted EPS of  —

— Late-Stage CNS Pipeline Progress Includes Enrollment Completion for Aripiprazole Lauroxil Pivotal Study and Fast Track Designation for ALKS 5461 —

--(BUSINESS WIRE)--Oct. 31, 2013--  (NASDAQ: ALKS) today reported financial results for the quarter ended . This is the second quarter of the nine-month period ending , as the company transitions to reporting on a calendar year basis.

"Against a backdrop of another quarter of solid financial performance,  is advancing one of the most important CNS pipelines in the biopharmaceutical industry," commented Richard Pops, Chief Executive Officer of . "During the quarter, we achieved key milestones for our most advanced programs. Looking forward, 2014 will be an important year for this late-stage pipeline as we obtain phase 3 results for aripiprazole lauroxil and prepare for the NDA submission and launch, as well as initiate the phase 3 program for ALKS 5461, which has been granted Fast Track status for the adjunctive treatment of major depressive disorder."

"This quarter's financial results demonstrate the power of our business model to generate substantial cash flows while also providing the resources to invest in our advancing pipeline," commented , Chief Financial Officer of . "Our commercial portfolio demonstrated another strong quarter with 38% year-over-year revenue growth from our key products."

Quarter Ended  Highlights

  • Total revenues for the quarter were , compared to total revenues of  for the same period in the prior year.
  • Revenues from the company's five key commercial products for the quarter grew 38% to , from  for the same period in the prior year.
  • Non-GAAP net income for the quarter was , or a non-GAAP diluted earnings per share (EPS) of . This compared to non-GAAP net income of , or a non-GAAP diluted EPS of , for the same period in the prior year.
  • GAAP net loss for the quarter was , or a basic and diluted GAAP loss per share of . This compared to GAAP net loss of , or a basic and diluted GAAP loss per share of , for the same period in the prior year.
  • Free cash flow for the quarter was , compared to  for the same period in the prior year.

Quarter Ended  Financial Results

Revenues

  • Manufacturing and royalty revenues from the company's long-acting atypical antipsychotic franchise, RISPERDAL® CONSTA®and INVEGA® SUSTENNA®/XEPLION®, were , compared to  for the same period in the prior year. Worldwide end-market sales of RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION were approximately , compared to approximately  in the same period in the prior year.
  • Manufacturing and royalty revenues from AMPYRA®/FAMPYRA®1 were , compared to  for the same period in the prior year.
  • Net sales of VIVITROL® were , compared to  for the same period in the prior year, representing an increase of approximately 26% year over year.
  • Royalty revenue from BYDUREON® was , compared to  for the same period in the prior year.
  • Results for the quarter included RITALIN LA®/FOCALIN XR® revenues of , VERELAN® revenues of  and® 145 revenues of . This compared to RITALIN LA/FOCALIN XR revenues of , VERELAN revenues of  and  145 revenues of  for the same period in the prior year.

Costs and Expenses

  • Operating expenses were , compared to operating expenses of  for the same period in the prior year.
  • Net interest expense was , compared to net interest expense of  for the same period in the prior year. The reduction was driven by the successful refinancing and repricing of the company's term loans completed in 2012 and 2013, respectively.

Balance Sheet

  • At ,  recorded cash and total investments of , compared to  at , and  at .

Financial Expectations for Nine Months Ending 

  • The company reiterated all of its financial expectations for the nine-month period ending , (originally provided on) except for Selling, General and Administrative expense, which the company now expects to be in the range of to , up from the previous range of , reflecting increased commercial activity in preparation for the aripiprazole lauroxil launch and activities related to the VIVITROL label update.
  • The company reiterated its expectations for non-GAAP net income to be in the range of  for the nine-month period ending , and expects to be in the upper end of that range.

Conference Call

 will host a conference call at  () on , to discuss these financial results and provide an update on the company. The conference call may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988. In addition, a replay of the conference call will be available from () on , through  () on , and may be accessed by visiting Alkermes' website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.

About 

 is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in ,  has an R&D center in ; a research and manufacturing facility in Athlone, ; and manufacturing facilities in  and . For more information, please visit Alkermes' website at www.alkermes.com.

Non-GAAP Financial Measures

This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income, non-GAAP diluted earnings per share and free cash flow. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

Management defines its non-GAAP financial measures as follows:

  • Non-GAAP net income adjusts for one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; non-cash tax expense; deferred revenue; and certain other one-time or non-cash items.
  • Free cash flow represents non-GAAP net income less capital expenditures.

Management believes that these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, better indicate underlying trends in ongoing operations and cash flows. However, non-GAAP net income, non-GAAP diluted earnings per share and free cash flow are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

Note Regarding Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to: statements concerning future financial and operating performance, business plans or prospects; the likelihood of continued revenue growth from the company's commercial products; the therapeutic and commercial value of the company's products; and the company's expectations concerning the timing and results of our clinical development activities. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond the company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements.

These risks and uncertainties include, among others: clinical development activities may not be completed on time or at all, and the results of such activities may not be successful, predictive of real-world results or of results in subsequent clinical trials; the company, and its partners, may not be able to continue to successfully commercialize its products; the , or regulatory authorities outside the U.S., may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks described in the  plc Annual Report for the year ended , and in other filings made by the company with the  ("SEC") and which are available on the SEC's website atwww.sec.gov, may occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The information contained in this press release is provided by the company as of the date hereof and, except as required by law, the company disclaims any intention or responsibility for updating any forward-looking information contained in this press release.

VIVITROL® is a registered trademark of ; RISPERDAL® CONSTA® and INVEGA® SUSTENNA® are registered trademarks of ; XEPLION® is a registered trademark of ; AMPYRA® and FAMPYRA®are registered trademarks of ; BYDUREON® is a registered trademark of ; ®is a registered trademark of Fournier Industrie et ; RITALIN LA® and FOCALIN XR® are registered trademarks of; and VERELAN® is a registered trademark of .

1AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg is developed and marketed in the U.S. by  and outside the U.S. by , under a licensing agreement with , as FAMPYRA® (prolonged-release fampridine tablets).

See full press release with financial tables here.

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.